236 related articles for article (PubMed ID: 24628949)
1. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin.
Li X; Yao R; Yue L; Qiu W; Qi W; Liu S; Yao Y; Liang J
J Cell Mol Med; 2014 May; 18(5):811-23. PubMed ID: 24628949
[TBL] [Abstract][Full Text] [Related]
2. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel.
Li X; Qiu W; Liu B; Yao R; Liu S; Yao Y; Liang J
J Transl Med; 2013 Sep; 11():204. PubMed ID: 24004449
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
Okada K; Fujiwara Y; Takahashi T; Nakamura Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Mori M; Doki Y
Ann Surg Oncol; 2013 Mar; 20(3):1035-43. PubMed ID: 23054116
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of Chemosensitivity by Stathmin-1 Silencing in Gastric Cancer Cells In Situ and In Vivo.
Meng ZJ; Tao K
Oncol Res; 2016 Jan; 23(1-2):35-41. PubMed ID: 26802649
[TBL] [Abstract][Full Text] [Related]
5. The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells.
Hu CJ; Wang B; Tang B; Chen BJ; Xiao YF; Qin Y; Yong X; Luo G; Zhang JW; Zhang D; Li S; He F; Yang SM
Biochim Biophys Acta; 2015 Mar; 1849(3):290-9. PubMed ID: 25482013
[TBL] [Abstract][Full Text] [Related]
6. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of the FoxM1 enhances the sensitivity of gastric cancer cells to cisplatin by targeting Mcl-1.
Li X; Liang J; Liu YX; Wang Y; Yang XH; Bao-Hongluan ; Zhang GL; Du J; Wu XH
Pharmazie; 2016 Jun; 71(6):345-8. PubMed ID: 27455555
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 is up-regulated in gastric cancer and its inhibition leads to cellular senescence, partially dependent on p27 kip1.
Zeng J; Wang L; Li Q; Li W; Björkholm M; Jia J; Xu D
J Pathol; 2009 Aug; 218(4):419-27. PubMed ID: 19235838
[TBL] [Abstract][Full Text] [Related]
9. Thiostrepton confers protection against reactive oxygen species-related apoptosis by restraining FOXM1-triggerred development of gastric cancer.
Liu SX; Zhou Y; Zhao L; Zhou LS; Sun J; Liu GJ; Du YS; Zhou YN
Free Radic Biol Med; 2022 Nov; 193(Pt 1):385-404. PubMed ID: 36152915
[TBL] [Abstract][Full Text] [Related]
10. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
11. FoxM1 mediates resistance to herceptin and paclitaxel.
Carr JR; Park HJ; Wang Z; Kiefer MM; Raychaudhuri P
Cancer Res; 2010 Jun; 70(12):5054-63. PubMed ID: 20530690
[TBL] [Abstract][Full Text] [Related]
12. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression.
Wang WD; Shang Y; Wang C; Ni J; Wang AM; Li GJ; Su L; Chen SZ
Acta Pharmacol Sin; 2022 Nov; 43(11):2956-2966. PubMed ID: 35422085
[TBL] [Abstract][Full Text] [Related]
13. FOXM1 confers acquired cisplatin resistance in breast cancer cells.
Kwok JM; Peck B; Monteiro LJ; Schwenen HD; Millour J; Coombes RC; Myatt SS; Lam EW
Mol Cancer Res; 2010 Jan; 8(1):24-34. PubMed ID: 20068070
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
Jiang L; Wang P; Chen L; Chen H
Int J Clin Exp Pathol; 2014; 7(9):5450-60. PubMed ID: 25337187
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
[TBL] [Abstract][Full Text] [Related]
16. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Li M; Yang J; Zhou W; Ren Y; Wang X; Chen H; Zhang J; Chen J; Sun Y; Cui L; Liu X; Wang L; Wu C
Br J Cancer; 2017 Sep; 117(7):974-983. PubMed ID: 28850563
[TBL] [Abstract][Full Text] [Related]
17. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.
Liu J; Li J; Wang K; Liu H; Sun J; Zhao X; Yu Y; Qiao Y; Wu Y; Zhang X; Zhang R; Yang A
Signal Transduct Target Ther; 2021 Feb; 6(1):42. PubMed ID: 33526768
[TBL] [Abstract][Full Text] [Related]
18. FoxM1 inhibition enhances chemosensitivity of docetaxel-resistant A549 cells to docetaxel via activation of JNK/mitochondrial pathway.
Wang K; Zhu X; Zhang K; Zhu L; Zhou F
Acta Biochim Biophys Sin (Shanghai); 2016 Sep; 48(9):804-9. PubMed ID: 27521795
[TBL] [Abstract][Full Text] [Related]
19. Twist1 promotes gastric cancer cell proliferation through up-regulation of FoxM1.
Qian J; Luo Y; Gu X; Zhan W; Wang X
PLoS One; 2013; 8(10):e77625. PubMed ID: 24204899
[TBL] [Abstract][Full Text] [Related]
20. Expression of Forkhead box M1 in soft tissue leiomyosarcoma: Clinicopathologic and in vitro study using a newly established cell line.
Maekawa A; Kohashi K; Setsu N; Kuda M; Iura K; Ishii T; Matsunobu T; Nakatsura T; Iwamoto Y; Oda Y
Cancer Sci; 2016 Jan; 107(1):95-102. PubMed ID: 26560505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
